Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy

“The cautionary note is this all has to be confirmed in a larger trial,” says Douglas Ingram, Sarepta’s president and chief executive. “Our goal is to bring this therapy rapidly to patients around the world,” Ingram says.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news